Recovery of endocrine function after islet and pancreas transplantation

Current Diabetes Reports

Volumn 12, Issue 5, 2012, Pages 587-596

  Rickels, Michael R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

cell secretory capacity; C peptide response; Endocrine function; Functional cell mass; Glucagon secretion; Glucose counter regulation; Hypoglycemia unawareness; Immunosuppression drugs; Insulin secretion; Insulin sensitivity; Islet and pancreas transplantation; Mycophenolate; Prednisone; Proinsulin secretion; Sirolimus; Tacrolimus; Type 1 diabetes

Indexed keywords

C PEPTIDE; CALCINEURIN INHIBITOR; ETANERCEPT; EXENDIN 4; GLUCAGON; GLUCOSE; INSULIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ARTICLE; ENDOCRINE FUNCTION; GLUCAGON RELEASE; GRAFT RECIPIENT; GRAFT REJECTION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN SENSITIVITY; INSULIN TREATMENT; LOW DRUG DOSE; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET TRANSPLANTATION; PANCREAS TRANSPLANTATION; POSTOPERATIVE PERIOD; SURGICAL TECHNIQUE; THERAPY EFFECT;

DIABETES MELLITUS, TYPE 1; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISLETS OF LANGERHANS TRANSPLANTATION; PANCREAS TRANSPLANTATION;

EID: 84870796039     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-012-0294-3     Document Type: Article

References (100)

1. Ludwig B, Ludwig S, Steffen A, Saeger HD, Bornstein SR. Islet vs pancreas transplantation in type 1 diabetes: competitive or complementary? Curr Diab Rep. 2010;10:506-11.
2. Frank A, Deng SP, Huang XL, et al. Transplantation for type 1 diabetes -Comparison of vascularized whole-organ pancreas with isolated pancreatic islets. Ann Surg. 2004;240:631-40.
3. Gruessner AC, Sutherland DE. Pancreas transplant outcomes for United States (US) and non-US cases as reported to the United Network for Organ Sharing (UNOS) and the International Pancreas Transplant Registry (IPTR) as of June 2004. Clin Transplant. 2005;19:433-55. (Pubitemid 40990653)
4. Barton FB, Rickels MR, Alejandro R, et al. Improvement in outcomes of clinical islet transplantation: 1999-2010. Diabetes Care. 2012;35:1436-45.
5. Sollinger HW, Odorico JS, Becker YT, D'Alessandro AM, Pirsch JD. One thousand simultaneous pancreas-kidney transplants at a single center with 22-year follow-up. Ann Surg. 2009;250:618-30.
6. Gruessner AC, Sutherland DE, Gruessner RW. Long-term outcome after pancreas transplantation. Curr Opin Organ Transplant. 2012;17:100-5.
7. Larsen MO, Rolin B, Sturis J, et al. Measurements of insulin responses as predictive markers of pancreatic beta-cell mass in normal and beta-cell-reduced lean and obese Gottingen minipigs in vivo. Am J Physiol Endocrinol Metab. 2006;290:E670-7.
8. Seaquist ER, Robertson RP. Effects of hemipancreatectomy on pancreatic alpha and beta cell function in healthy human donors. J Clin Invest. 1992;89:1761-6.
9. Christiansen E, Tibell A, Volund A, et al. Pancreatic endocrine function in recipients of segmental and whole pancreas transplantation. J Clin Endocrinol Metab. 1996;81:3972-9. (Pubitemid 26380404)
10. Robertson RP, Sutherland DE, Lanz KJ. Normoglycemia and preserved insulin secretory reserve in diabetic patients 10-18 years after pancreas transplantation. Diabetes. 1999;48:1737-40. (Pubitemid 29415191)
11. Robertson RP. Consequences on beta-cell function and reserve after long-term pancreas transplantation. Diabetes. 2004;53:633-44. (Pubitemid 38270632)
12. Teuscher AU, Kendall DM, Smets YF, Leone JP, Sutherland DE, Robertson RP. Successful islet autotransplantation in humans: functional insulin secretory reserve as an estimate of surviving islet cell mass. Diabetes. 1998;47:324-30. (Pubitemid 28104191)
13. Greenbaum CJ, Prigeon RL, D'Alessio DA. Impaired beta-cell function, incretin effect, and glucagon suppression in patients with type 1 diabetes who have normal fasting glucose. Diabetes. 2002;51:951-7. (Pubitemid 34438336)
14. Keymeulen B, Vandemeulebroucke E, Ziegler AG, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med. 2005;352:2598-608. (Pubitemid 41007846)
15. The DCCT Research Group. Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual beta-cell function: observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT). J Clin Endocrinol Metab. 1987;65:30-6.
16. The Diabetes Control and Complications Trial Research Group. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. Ann Intern Med. 1998;128:517-23.
17. Tsai EB, Sherry NA, Palmer JP, Herold KC. The rise and fall of insulin secretion in type 1 diabetes mellitus. Diabetologia. 2006;49:261-70. (Pubitemid 43185394)
18. Steffes MW, Sibley S, Jackson M, Thomas W. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care. 2003;26:832-6. (Pubitemid 36929351)
19. The Diabetes. Control and Complications Trial Research Group. Hypoglycemia in the diabetes control and complications trial. Diabetes. 1997;46:271-86.
20. Fukuda M, Tanaka A, Tahara Y, et al. Correlation between minimal secretory capacity of pancreatic beta-cells and stability of diabetic control. Diabetes. 1988;37:81-8. (Pubitemid 18036462)
21. Clinical Islet Transplantation Study. Available at: http://www. isletstudy.org/. Accessed May 2012.
22. Faradji RN, Monroy K, Messinger S, et al. Simple measures to monitor beta-cell mass and assess islet graft dysfunction. Am J Transplant. 2007;7:303-8. (Pubitemid 46096323)
23. Shapiro AM. State of the art of clinical islet transplantation and novel protocols of immunosuppression. Curr Diab Rep. 2011;11:345-54.
24. Kaufman DB, Morel P, Field MJ, Munn SR, Sutherland DER. Purified canine islet autografts-functional outcome as influenced by islet number and implantation site. Transplantation. 1990;50:385-91. (Pubitemid 20309856)
25. Andersson A, Korsgren O, Jansson L. Intraportally transplanted pancreatic-islets revascularized from hepatic arterial system. Diabetes. 1989;38:192-5. (Pubitemid 19029277)
26. Faradji RN, Monroy K, Cure P, et al. C-peptide and glucose values in the peritransplant period after intraportal islet infusions in type 1 diabetes. Transplant Proc. 2005;37:3433-4. (Pubitemid 41659911)
27. Hirshberg B, Mog S, Patterson N, Leconte J, Harlan DM. Histopathological study of intrahepatic islets transplanted in the nonhuman primate model using Edmonton protocol immunosuppression. J Clin Endocrinol Metab. 2002;87:5424-9. (Pubitemid 36034338)
28. Davalli AM, Ricordi C, Socci C, et al. Abnormal sensitivity to glucose of human islets cultured in a high glucose medium: partial reversibility after an additional culture in a normal glucose medium. J Clin Endocrinol Metab. 1991;72:202-8. (Pubitemid 21921676)
29. Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in 7 patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med. 2000;343:230-8. (Pubitemid 30490390)
30. Shapiro AMJ, Ricordi C, Hering BJ, et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med. 2006;355:1318-30. (Pubitemid 44465460)
31. Ryan EA, Shandro T, Green K, et al. Assessment of the severity of hypoglycemia and glycemic lability in type 1 diabetic subjects undergoing islet transplantation. Diabetes. 2004;53:955-62. (Pubitemid 38436607)
32. Rickels MR, Schutta MH, Markmann JF, Barker CF, Naji A, Teff KL. Beta-cell function following human islet transplantation for type 1 diabetes. Diabetes. 2005;54:100-6. (Pubitemid 40105100)
33. Paty BW, Imes S, Ryan EA, Senior PA, Robertson RP, Shapiro AMJ. Insulin secretory reserve as a measure of functional islet mass following islet allotransplantation in type 1 diabetes [abstract]. Diabetes. 2004;53 Suppl 2:A35-6.
34. Keymeulen B, Gillard P, Mathieu C, et al. Correlation between beta cell mass and glycemic control in type 1 diabetic recipients of islet cell graft. Proc Nat Acad Sci U S A. 2006;103:17444-9. (Pubitemid 44788988)
35. Eriksson O, Eich T, Sundin A, et al. Positron emission tomography in clinical islet transplantation. Am J Transplant. 2009;9:2816-24.
36. Rickels MR, Naji A, Teff KL. Insulin sensitivity, glucose effectiveness, and free fatty acid dynamics after human islet transplantation for type 1 diabetes. J Clin Endocrinol Metab. 2006;91:2138-44. (Pubitemid 43854996)
37. Hirsch D, Odorico J, Radke N, et al. Correction of insulin sensitivity and glucose disposal after pancreatic islet transplantation: preliminary results. Diabetes Obes Metab. 2010;12:994-1003.
38. Lopez-Talavera JC, Garcia-Ocana A, Sipula I, Takane KK, Cozar-Castellano I, Stewart AF. Hepatocyte growth factor gene therapy for pancreatic islets in diabetes: reducing the minimal islet transplant mass required in a glucocorticoid-free rat model of allogeneic portal vein islet transplantation. Endocrinology. 2004;145:467-74. (Pubitemid 38183786)
39. Rickels MR, Mueller R, Teff KL, Naji A. Beta-cell secretory capacity and demand in recipients of islet, pancreas, and kidney transplants. J Clin Endocrinol Metab. 2010;95:1238-46.
40. Soleimanpour SA, Hirshberg B, Bunnell DJ, et al. Metabolic function of a suboptimal transplanted islet mass in non-human primates on rapamycin monotherapy. Cell Transplant. 2011. doi:10.3727/096368911X603620.
41. Seaquist ER, Kahn SE, Clark PM, Hales CN, Porte D, Robertson RP. Hyperproinsulinemia is associated with increased beta cell demand after hemipancreatectomy in humans. J Clin Invest. 1996;97:455-60. (Pubitemid 26039410)
42. McDonald CG, Ryan EA, Paty BW, et al. Cross-sectional and prospective association between proinsulin secretion and graft function after clinical islet transplantation. Transplantation. 2004;78:934-7. (Pubitemid 39298541)
43. Klimek AM, Soukhatcheva G, Thompson DM, et al. Impaired proinsulin processing is a characteristic of transplanted islets. Am J Transplant. 2009;9:2119-25.
44. Hostens K, Ling ZD, Van Schravendijk C, Pipeleers D. Prolonged exposure of human beta-cells to high glucose increases their release of proinsulin during acute stimulation with glucose or arginine. J Clin Endocrinol Metab. 1999;84:1386-90. (Pubitemid 30644404)
45. Rickels MR, Naji A. Proinsulin processing and transplanted islets. Am J Transplant. 2010;10:1495.
46. Westermark GT, Westermark P, Berne C, Korsgren O. Widespread amyloid deposition in transplanted human pancreatic islets. N Engl J Med. 2008;359:977-9.
47. Westermark GT, Davalli AM, Secchi A, et al. Further evidence for amyloid deposition in clinical pancreatic islet grafts. Transplantation. 2012;93:219-23.
48. Ritzel RA, Meier JJ, Lin CY, Veldhuis JD, Butler PC. Human islet amyloid polypeptide oligomers disrupt cell coupling, induce apoptosis, and impair insulin secretion in isolated human islets. Diabetes. 2007;56:65-71.
49. Kahn SE, Dalessio DA, Schwartz MW, et al. Evidence of cosecretion of islet amyloid polypeptide and insulin by beta-cells. Diabetes. 1990;39:634-8. (Pubitemid 20223792)
50. Westermark P, Li ZC, Westermark GT, Leckstrom A, Steiner DF. Effects of beta cell granule components on human islet amyloid polypeptide fibril formation. FEBS Lett. 1996;379:203-6. (Pubitemid 26049441)
51. Rickels MR, Collins HW, Naji A. Amyloid and transplanted islets. N Engl J Med. 2008;359:2729-31.
52. Liu C, Koeberlein B, Feldman MD, et al. Accumulation of intrahepatic islet amyloid in a nonhuman primate transplant model. Endocrinology. 2012;153:1673-83.
53. The CITR Research Group. 2007 update on allogeneic islet transplantation from the Collaborative Islet Transplant Registry (CITR). Cell Transplant. 2009;18:753-67.
54. Koh A, Senior P, Salam A, et al. Insulin-heparin infusions peritransplant substantially improve single-donor clinical islet transplant success. Transplantation. 2010;89:465-71.
55. Hering BJ, Kandaswamy R, Ansite JD, et al. Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes. JAMA. 2005;293:830-5. (Pubitemid 40250366)
56. Bellin MD, Kandaswamy R, Parkey J, et al. Prolonged insulin independence after islet allotransplants in recipients with type 1 diabetes. Am J Transplant. 2008;8:2463-70.
57. Bellin MD, Barton FB, Heitman A, et al. Potent induction immunotherapy promotes long-terminsulin independence after islet transplantation in type 1 diabetes. Am J Transplant. 2012;12:1576-83.
58. Rickels MR, Chiou AJ, Fuller C, et al. Beta-cell secretory capacity after human islet transplantation by the CIT07 vs Edmonton protocol: preliminary results [abstract]. Am J Transplant. 2011;11 Suppl 2:79-80.
59. Faradji RN, Tharavanij T, Messinger S, et al. Long-term insulin independence and improvement in insulin secretion after supplemental islet infusion under exenatide and etanercept. Transplantation. 2008;86:1658-65.
60. Farilla L, Bulotta A, Hirshberg B, et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology. 2003;144:5149-58. (Pubitemid 37476040)
61. Gangemi A, Salehi P, Hatipoglu B, et al. Islet transplantation for brittle type 1 diabetes: The UIC Protocol. Am J Transplant. 2008;8:1-12.
62. Al Ghofaili K, Fung M, Ao ZL, et al. Effect of exenatide on beta cell function after islet transplantation in type 1 diabetes. Transplantation. 2007;83:24-8. (Pubitemid 46104966)
63. Froud T, Faradji RN, Pileggi A, et al. The use of exenatide in islet transplant recipients with chronic allograft dysfunction: safety, efficacy, and metabolic effects. Transplantation. 2008;86:36-45.
64. Rickels MR, Mueller R, Markman JF, Naji A. Effect of GLP-1 on beta-and alpha-cell function in isolated islet and whole pancreas transplant recipients. J Clin Endocrinol Metab. 2009;94:181-9.
65. Tan M, Kandaswamy R, Sutherland DE, Gruessner RW, Gruessner AC, Humar A. Risk factors and impact of delayed graft function after pancreas transplants. Am J Transplant. 2004;4:758-62. (Pubitemid 38637574)
66. Diem P, Abid M, Redmon JB, Sutherland DER, Robertson RP. Systemic venous drainage of pancreas allografts as independent cause of hyperinsulinemia in type-I diabetic recipients. Diabetes. 1990;39:534-40. (Pubitemid 20223777)
67. Teuscher AU, Seaquist ER, Robertson RP. Diminished insulin secretory reserve in diabetic pancreas transplant and nondiabetic kidney transplant recipients. Diabetes. 1994;43:593-8. (Pubitemid 24096302)
68. Cottrell DA. Normalization of insulin sensitivity and glucose homeostasis in type I diabetic pancreas transplant recipients: A 48-month cross-sectional study-a clinical research center study. J Clin Endocrinol Metab. 1996;81:3513-9. (Pubitemid 26339908)
69. Midtvedt K, Hjelmesaeth J, Hartmann A, et al. Insulin resistance after renal transplantation: The effect of steroid dose reduction and withdrawal. J Am Soc Nephrol. 2004;15:3233-9. (Pubitemid 39578856)
70. Gillard P, Vandemeulebroucke E, Keymeulen B, et al. Functional beta-cell mass and insulin sensitivity is decreased in insulinindependent pancreas-kidney recipients. Transplantation. 2009;87:402-7.
71. Robertson RP, Lanz KJ, Sutherland DE, Seaquist ER. Relationship between diabetes and obesity 9 to 18 years after hemipancreatectomy and transplantation in donors and recipients. Transplantation. 2002;73:736-41. (Pubitemid 34260569)
72. Heller SR, Choudhary P, Davies C, et al. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia. 2007;50:1140-7. (Pubitemid 46701541)
73. Gerich JE, LangloisM, Noacco C, KaramJH, Forsham PH. Lack of glucagon response to hypoglycemia in diabetes: evidence for an intrinsic pancreatic alpha cell defect. Science. 1973;182:171-3.
74. Cooperberg BA, Cryer PE. Insulin reciprocally regulates glucagon secretion in humans. Diabetes. 2010;59:2936-40.
75. Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes. Diabetes Care. 2003;26:1902-12. (Pubitemid 36929141)
76. Pedersen-Bjergaard U, Pramming S, Heller SR, et al. Severe hypoglycaemia in 1076 adult patients with type 1 diabetes: influence of risk markers and selection. Diabetes Metab Res Rev. 2004;20:479-86. (Pubitemid 40028649)
77. Cryer PE. Mechanisms of hypoglycemia-associated autonomic failure and its component syndromes in diabetes. Diabetes. 2005;54:3592-601. (Pubitemid 43334356)
78. Fanelli CG, Epifano L, Rambotti AM, et al. Meticulous prevention of hypoglycemia normalizes the glycemic thresholds and magnitude of most of neuroendocrine responses to, symptoms of, and cognitive function during hypoglycemia in intensively treated patients with short-term IDDM. Diabetes. 1993;42:1683-9. (Pubitemid 23318128)
79. Cranston I, Lomas J, Maran A, Macdonald I, Amiel SA. Restoration of hypoglycemia awareness in patients with long-duration insulin-dependent diabetes. Lancet. 1994;344:283-7. (Pubitemid 24230294)
80. Dagogojack S, Rattarasarn C, Cryer PE. Reversal of hypoglycemia unawareness, but not defective glucose counter-regulation, in IDDM. Diabetes. 1994;43:1426-34.
81. Rickels MR, Schutta MH, Mueller R, et al. Islet cell hormonal responses to hypoglycemia after human islet transplantation for type 1 diabetes. Diabetes. 2005;54:3205-11. (Pubitemid 43334376)
82. Kendall DM, Teuscher AU, Robertson RP. Defective glucagon secretion during sustained hypoglycemia following successful islet allo-and autotransplantation in humans. Diabetes. 1997;46:23-7. (Pubitemid 27009944)
83. Paty BW, Ryan EA, Shapiro AMJ, Lakey JRT, Robertson RP. Intrahepatic islet transplantation in type 1 diabetic patients does not restore hypoglycemic hormonal counter-regulation or symptom recognition after insulin independence. Diabetes. 2002;51:3428-34. (Pubitemid 35403446)
84. Diamond MP, Hallarman L, Starickzych K, et al. Suppression of counter-regulatory hormone response to hypoglycemia by insulin per se. J Clin Endocrinol Metab. 1991;72:1388-90. (Pubitemid 21921859)
85. Rickels MR, Schutta MH, Mueller R, et al. Glycemic thresholds for activation of counter-regulatory hormone and symptom responses in islet transplant recipients. J Clin Endocrinol Metab. 2007;92:873-9. (Pubitemid 46465657)
86. Paty BW, Senior PA, Lakey JR, Shapiro AM, Ryan EA. Assessment of glycemic control after islet transplantation using the continuous glucose monitor in insulin-independent vs insulinrequiring type 1 diabetes subjects. Diabetes Technol Ther. 2006;8:165-73. (Pubitemid 43848039)
87. Heller SR, Cryer PE. Reduced neuroendocrine and symptomatic responses to subsequent hypoglycemia after 1 episode of hypoglycemia in nondiabetic humans. Diabetes. 1991;40:223-6.
88. Meyer C, Hering BJ, Grossmann R, et al. Improved glucose counter-regulation and autonomic symptoms after intraportal islet transplants alone in patients with long-standing type I diabetes mellitus. Transplantation. 1998;66:233-40. (Pubitemid 28370007)
89. Rickels MR, Cullison K, Fuller C, et al. Improvement of glucose counter-regulation following human islet transplantation in longstanding type 1 diabetes: preliminary results [abstract]. Diabetes. 2011;60 Suppl 1:293-OR.
90. Luzi L, Battezzati A, Perseghin G, et al. Lack of Feedback Inhibition of Insulin-Secretion in Denervated Human Pancreas. Diabetes. 1992;41:1632-9.
91. Kendall DM, Rooney DP, Smets YFC, Bolding LS, Robertson RP. Pancreas transplantation restores epinephrine response and symptom recognition during hypoglycemia in patients with longstanding type I diabetes and autonomic neuropathy. Diabetes. 1997;46:249-57. (Pubitemid 27272259)
92. Bolinder J, Wahrenberg H, Persson A, et al. Effect of pancreas transplantation on glucose counter-regulation in insulindependent diabetic-patients prone to severe hypoglycemia. J Intern Med. 1991;230:527-33.
93. Boden G, Chen XH, Desantis R, Kolaczynski J, Morris M. Evidence that suppression of insulin-secretion by insulin itself is neurally-mediated. Metab Clin Exp. 1993;42:786-9. (Pubitemid 23173422)
94. Gardemann A, Jungermann K, Grosse V, et al. Intraportal transplantation of pancreatic-islets into livers of diabetic rats-reinnervation of islets and regulation of insulin-secretion by the hepatic sympathetic-nerves. Diabetes. 1994;43:1345-52.
95. Diem P, Redmon JB, Abid M, et al. Glucagon, catecholamine and pancreatic-polypeptide secretion in type-I diabetic recipients of pancreas allografts. J Clin Invest. 1990;86:2008-13.
96. Battezzati A, Luzi L, Perseghin G, et al. Persistence of counterregulatory abnormalities in insulin-dependent diabetes-mellitus after pancreas transplantation. Eur J Clin Invest. 1994;24:751-8. (Pubitemid 24358561)
97. Paty BW, Lanz K, Kendall DM, Sutherland DER, Robertson RP. Restored hypoglycemic counter-regulation is stable in successful pancreas transplant recipients for up to 19 years after transplantation. Transplantation. 2001;72:1103-7. (Pubitemid 32924085)
98. Hoeldtke RD, Boden G, Shuman CR, Owen OE. Reduced epinephrine secretion and hypoglycemia unawareness in diabetic autonomic neuropathy. Ann Intern Med. 1982;96:459-62. (Pubitemid 12139872)
99. Meyer C, Grossmann R, Mitrakou A, et al. Effects of autonomic neuropathy on counter-regulation and awareness at hypoglycemia in type 1 diabetic patients. Diabetes Care. 1998;21:1960-6. (Pubitemid 28478301)
100. Barrou Z, Seaquist ER, Robertson RP. Pancreas transplantation in diabetic humans normalizes hepatic glucose-production during hypoglycemia. Diabetes. 1994;43:661-6. (Pubitemid 24138779)